一种针对结核病的Toll样受体2导向融合蛋白疫苗。
A Toll-like receptor-2-directed fusion protein vaccine against tuberculosis.
作者信息
Wang Baolin, Henao-Tamayo Marcela, Harton Marisa, Ordway Diane, Shanley Crystal, Basaraba Randall J, Orme Ian M
机构信息
Mycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO 80523, USA.
出版信息
Clin Vaccine Immunol. 2007 Jul;14(7):902-6. doi: 10.1128/CVI.00077-07.
Abstract
A fusion protein designated CSU-F36 was constructed that consisted of acylated Rv1411, a potent Toll-like receptor-2 agonist, fused to ESAT-6, a well-characterized immunogenic protein from Mycobacterium tuberculosis. The CSU-F36 fusion protein strongly induced interleukin 12 secretion from macrophages and induced the increased accumulation of CD4 T cells capable of secreting gamma interferon in the lungs of infected mice. These mice were significantly protected from low-dose aerosol challenge with M. tuberculosis, even with CSU-F36 delivered in a simple depot material. This "natural adjuvant"-containing system could potentially bypass the need for more expensive TH1-inducing adjuvants and could be applied to many mycobacterial proteins to provide effective and cheap new vaccines against tuberculosis.
摘要
构建了一种名为CSU-F36的融合蛋白，它由酰化的Rv1411（一种有效的Toll样受体2激动剂）与ESAT-6（一种来自结核分枝杆菌的特征明确的免疫原性蛋白）融合而成。CSU-F36融合蛋白强烈诱导巨噬细胞分泌白细胞介素12，并诱导感染小鼠肺部能够分泌γ干扰素的CD4 T细胞积累增加。这些小鼠在接受低剂量结核分枝杆菌气溶胶攻击时得到了显著保护，即使CSU-F36是通过一种简单的长效材料递送的。这种含有“天然佐剂”的系统可能无需使用更昂贵的TH1诱导佐剂，并且可应用于多种分枝杆菌蛋白，以提供有效且廉价的新型抗结核疫苗。
相似文献
1
A Toll-like receptor-2-directed fusion protein vaccine against tuberculosis.一种针对结核病的Toll样受体2导向融合蛋白疫苗。
Clin Vaccine Immunol. 2007 Jul;14(7):902-6. doi: 10.1128/CVI.00077-07.
2
Enhanced effect of BCG vaccine against pulmonary Mycobacterium tuberculosis infection in mice with lung Th17 response to mycobacterial heparin-binding hemagglutinin adhesin antigen.卡介苗对肺部对分枝杆菌肝素结合血凝素粘附抗原产生Th17应答的小鼠肺部结核分枝杆菌感染的增强作用。
Microbiol Immunol. 2015 Dec;59(12):735-43. doi: 10.1111/1348-0421.12340.
3
Rv2299c, a novel dendritic cell-activating antigen of Mycobacterium tuberculosis, fused-ESAT-6 subunit vaccine confers improved and durable protection against the hypervirulent strain HN878 in mice.Rv2299c，一种新型的结核分枝杆菌树突状细胞激活抗原，融合ESAT-6亚单位疫苗可增强并持久保护小鼠抵御高毒力菌株HN878。
Oncotarget. 2017 Mar 21;8(12):19947-19967. doi: 10.18632/oncotarget.15256.
4
Synthetic protein conjugate vaccines provide protection against in mice.合成蛋白缀合物疫苗可在小鼠中提供针对 的保护。
Proc Natl Acad Sci U S A. 2021 Jan 26;118(4). doi: 10.1073/pnas.2013730118.
5
GI-19007, a Novel Saccharomyces cerevisiae-Based Therapeutic Vaccine against Tuberculosis.GI-19007，一种新型的基于酿酒酵母的抗结核病治疗性疫苗。
Clin Vaccine Immunol. 2017 Dec 5;24(12). doi: 10.1128/CVI.00245-17. Print 2017 Dec.
6
Protective efficacy of a recombinant BCG secreting antigen 85B/Rv3425 fusion protein against Mycobacterium tuberculosis infection in mice.重组卡介苗分泌抗原 85B/Rv3425 融合蛋白对小鼠结核分枝杆菌感染的保护效力。
Hum Vaccin Immunother. 2012 Dec 1;8(12):1869-74. doi: 10.4161/hv.21817. Epub 2012 Aug 21.
7
Evaluation of protective efficacy conferred by a recombinant Mycobacterium bovis BCG expressing a fusion protein of Ag85A-ESAT-6.评估表达 Ag85A-ESAT-6 融合蛋白的重组牛分枝杆菌卡介苗的保护效力。
J Microbiol Immunol Infect. 2014 Feb;47(1):48-56. doi: 10.1016/j.jmii.2012.11.005. Epub 2013 Jan 26.
8
TLR2-targeted secreted proteins from Mycobacterium tuberculosis are protective as powdered pulmonary vaccines.结核分枝杆菌 TLR2 靶向分泌蛋白作为粉末状肺部疫苗具有保护作用。
Vaccine. 2013 Sep 13;31(40):4322-9. doi: 10.1016/j.vaccine.2013.07.022. Epub 2013 Jul 20.
9
Heterologous Boost Following Reduces the Late Persistent, Rather Than the Early Stage of Intranasal Tuberculosis Challenge Infection.异源加强接种可减少迟发性而非早期鼻内结核感染挑战。
Front Immunol. 2018 Oct 30;9:2439. doi: 10.3389/fimmu.2018.02439. eCollection 2018.
10
Influence of ESAT-6 secretion system 1 (RD1) of Mycobacterium tuberculosis on the interaction between mycobacteria and the host immune system.结核分枝杆菌ESAT-6分泌系统1（RD1）对分枝杆菌与宿主免疫系统相互作用的影响。
J Immunol. 2005 Mar 15;174(6):3570-9. doi: 10.4049/jimmunol.174.6.3570.
引用本文的文献
1
Proteome Profile Changes Induced by Heterologous Overexpression of -Derived Antigens PstS-1 (Rv0934) and Ag85B (Rv1886c) in .异源过表达 - 衍生抗原 PstS-1（Rv0934）和 Ag85B（Rv1886c）诱导的 中的蛋白质组谱变化。
Biomolecules. 2022 Dec 8;12(12):1836. doi: 10.3390/biom12121836.
2
GI-19007, a Novel Saccharomyces cerevisiae-Based Therapeutic Vaccine against Tuberculosis.GI-19007，一种新型的基于酿酒酵母的抗结核病治疗性疫苗。
Clin Vaccine Immunol. 2017 Dec 5;24(12). doi: 10.1128/CVI.00245-17. Print 2017 Dec.
3
Mycobacterium tuberculosis Rv3628 drives Th1-type T cell immunity via TLR2-mediated activation of dendritic cells and displays vaccine potential against the hyper-virulent Beijing K strain.结核分枝杆菌Rv3628通过Toll样受体2介导的树突状细胞激活驱动1型辅助性T细胞免疫，并显示出针对高毒力北京K菌株的疫苗潜力。
Oncotarget. 2016 May 3;7(18):24962-82. doi: 10.18632/oncotarget.8771.
4
Dendritic cell targeted vaccines: Recent progresses and challenges.树突状细胞靶向疫苗：最新进展与挑战
Hum Vaccin Immunother. 2016 Mar 3;12(3):612-22. doi: 10.1080/21645515.2015.1105415.
5
From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3+GLA-SE.从鼠到人：候选利什曼病疫苗 LEISH-F3+GLA-SE 的安全性、免疫原性和疗效。
Clin Transl Immunology. 2015 Apr 10;4(4):e35. doi: 10.1038/cti.2015.6. eCollection 2015 Apr.
6
Vaccines for TB: Lessons from the Past Translating into Future Potentials.结核病疫苗：从过去汲取的教训转化为未来的潜力。
J Immunol Res. 2015;2015:916780. doi: 10.1155/2015/916780. Epub 2015 Jun 3.
7
Dendritic cell-targeted vaccines--hope or hype?树突状细胞靶向疫苗——希望还是炒作？
Nat Rev Immunol. 2014 Oct;14(10):705-11. doi: 10.1038/nri3727. Epub 2014 Sep 5.
8
Targeting TLR2 for vaccine development.针对 TLR2 进行疫苗开发。
J Immunol Res. 2014;2014:619410. doi: 10.1155/2014/619410. Epub 2014 Jun 26.
9
Role of Fused Mycobacterium tuberculosis Immunogens and Adjuvants in Modern Tuberculosis Vaccines.融合结核分枝杆菌免疫原和佐剂在现代结核病疫苗中的作用。
Front Immunol. 2014 Apr 23;5:188. doi: 10.3389/fimmu.2014.00188. eCollection 2014.
10
TLR2 engagement on CD4(+) T cells enhances effector functions and protective responses to Mycobacterium tuberculosis.TLR2 与 CD4(+) T 细胞的相互作用增强了对结核分枝杆菌的效应功能和保护应答。
Eur J Immunol. 2014 May;44(5):1410-21. doi: 10.1002/eji.201344100. Epub 2014 Mar 14.
本文引用的文献
1
Aggravated infection in mice co-administered with Mycobacterium tuberculosis and the 27-kDa lipoprotein.在与结核分枝杆菌和27-kDa脂蛋白共同给药的小鼠中感染加剧。
Microbes Infect. 2006 Jun;8(7):1750-7. doi: 10.1016/j.micinf.2006.02.011. Epub 2006 Apr 24.
2
Pseudo-rationale design of efficient TB vaccines: lesson from the mycobacterial 27-kDa lipoprotein.高效结核病疫苗的伪理性设计：来自分枝杆菌27 kDa脂蛋白的启示
Tuberculosis (Edinb). 2006 May-Jul;86(3-4):225-35. doi: 10.1016/j.tube.2006.01.012. Epub 2006 Mar 3.
3
Preclinical testing of new vaccines for tuberculosis: a comprehensive review.新型结核病疫苗的临床前测试：全面综述
Vaccine. 2006 Jan 9;24(1):2-19. doi: 10.1016/j.vaccine.2005.07.078. Epub 2005 Aug 8.
4
The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs.在感染结核分枝杆菌的豚鼠中，将牛分枝杆菌卡介苗与结核分枝杆菌72千道尔顿融合多蛋白Mtb72F共同给药，可增强牛分枝杆菌卡介苗的保护作用。
Infect Immun. 2004 Nov;72(11):6622-32. doi: 10.1128/IAI.72.11.6622-6632.2004.
5
A limited antigen-specific cellular response is sufficient for the early control of Mycobacterium tuberculosis in the lung but is insufficient for long-term survival.有限的抗原特异性细胞反应足以在早期控制肺部结核分枝杆菌，但不足以实现长期存活。
Infect Immun. 2004 Jul;72(7):3759-68. doi: 10.1128/IAI.72.7.3759-3768.2004.
6
Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein.结核多蛋白疫苗Mtb72F的组分以裸DNA或重组蛋白形式递送时所诱导的差异性免疫反应和保护效力。
J Immunol. 2004 Jun 15;172(12):7618-28. doi: 10.4049/jimmunol.172.12.7618.
7
The Mycobacterium tuberculosis recombinant 27-kilodalton lipoprotein induces a strong Th1-type immune response deleterious to protection.结核分枝杆菌重组27千道尔顿脂蛋白可诱导产生强烈的Th1型免疫反应，对保护作用有害。
Infect Immun. 2003 Jun;71(6):3146-54. doi: 10.1128/IAI.71.6.3146-3154.2003.
8
The TB epidemic from 1992 to 2002.1992年至2002年的结核病流行情况。
Tuberculosis (Edinb). 2003;83(1-3):4-14. doi: 10.1016/s1472-9792(02)00071-9.
9
Dynamics of gamma interferon, interleukin-12 (IL-12), IL-10, and transforming growth factor beta mRNA expression in primary Mycobacterium bovis BCG infection in guinea pigs measured by a real-time fluorogenic reverse transcription-PCR assay.通过实时荧光逆转录聚合酶链反应检测豚鼠原发性牛分枝杆菌卡介苗感染中γ干扰素、白细胞介素-12（IL-12）、IL-10和转化生长因子β mRNA表达的动态变化。
Infect Immun. 2002 Dec;70(12):6614-20. doi: 10.1128/IAI.70.12.6614-6620.2002.
10
Control of Mycobacterium tuberculosis through mammalian Toll-like receptors.通过哺乳动物Toll样受体控制结核分枝杆菌。
Curr Opin Immunol. 2002 Aug;14(4):452-7. doi: 10.1016/s0952-7915(02)00355-2.
Zotero 插件